Monday, January 30, 2012 at 06:29AM Scottish Enterprise offers Innovation Support for the Development of Aquila BioMedical's Contract Pain Services. This will allow Aquila to progress in its expansion of services, and accelerate growth.
Tuesday, January 3, 2012 at 06:21AM Aquila BioMedical is very pleased to announce the receipt of SMART:SCOTLAND funding for the purpose of developing the innovative MBP-tracker model. This technology will provide opportunity to the Pharmaceutical Industry to gain access to high value mechanism of action tools which will be relevant to the investigation of a range of T cell mediated autoimmune diseases, including Multiple Sclerosis. We look forward to discussing this with interested parties.
Monday, December 5, 2011 at 09:11AM Aquila BioMedical appoints COO to drive leadership, quality and rapid growth of it's service offerings. The COO brings a wealth of experience from over 12 years in contract Preclinical GLP services. The chairman of Aquila states 'We are very excited to have our new COO on board and anticipate that the experience and contacts that come from this appointment will be critical for Aquila's future success. Furthermore, this appointment will accelerate Aquila's expansion into other service areas.' Feel free to contact us for more information on our future plans.
Wednesday, November 30, 2011 at 04:21AM Today Aquila announces its core Research and Development Strategy in the areas of MS, Autoimmune disease, Inflammation and Pain which will underpin the focus of the company over the next year. This will provide a unique service platform for the development of compounds within these therapeutic areas.
Wednesday, November 23, 2011 at 08:43AM We are delighted to launch our new website that we have been working hard on over the last couple of months. Feel free to let us know what you think.